Experience

Deerfield Management

• United States
• Investment Management
• 1 - 100 Employee

• Senior Director, In Vitro Pharmacology

  • Jan 2022 - Present

• Director, In Vitro Pharmacology (3DC)

  • May 2020 - Dec 2021



Inzen Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Director

  • Oct 2017 - May 2020



Kadmon, a Sanofi Company

• United States
• Biotechnology Research
• 1 - 100 Employee

• Principal Scientist

  • Jan 2014 - Sep 2017



Pfizer

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Post-doctoral Fellow

  • Aug 2011 - Dec 2013

  Cancer epigenetics Cancer epigenetics



Columbia University

• United States
• Higher Education
• 700 & Above Employee

• Graduate Student in Biological Sciences

  • Sep 2005 - Jul 2011

  During the pursuit of my PhD in Biology at Columbia University, I worked in the lab of Dr. Carol Prives. Using molecular biological and biochemical tools I conducted research on the tumor suppressor protein p53. The function of this protein is lost in over half of human tumors. Given its importance in cancer biology, I studied the properties of p53 in an attempt to understand what functions of p53 contribute to its tumor-suppressive properties. During the pursuit of my PhD in Biology at Columbia University, I worked in the lab of Dr. Carol Prives. Using molecular biological and biochemical tools I conducted research on the tumor suppressor protein p53. The function of this protein is lost in over half of human tumors. Given its importance in cancer biology, I studied the properties of p53 in an attempt to understand what functions of p53 contribute to its tumor-suppressive properties.